Why the study?
More information was needed relating to the effectiveness of ticagrelor versus clopidogrel among patients undergoing PCI for ACS.
Does ticagrelor reduce mortality and ischemic events compared to clopidogrel in patients undergoing PCI for ACS?
Does ticagrelor reduce mortality and ischemic events compared to clopidogrel in patients undergoing PCI for ACS?
In patients undergoing PCI for ACS, ticagrelor is superior to clopidogrel in reducing all-cause mortality, MI, and stroke, but is associated with a higher risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Favors ticagrelor over clopidogrel in ACS PCI despite bleeding; challenges prior low-certainty evidence against benefit.
Maqbool et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: